【患者关心】培美替尼治疗肝内胆管癌的疗效分析

In 2020, pemigatinib was approved for marketing in the United States, based on the results of a clinical trial in which 107 patients with locally advanced or metastatic cholangiocarcinoma participated. The trial results showed that the overall response rate (ORR) of pemetinib reached 36%, of which 2.8% of patients had complete response and 33% of patients had partial response. Among patients who responded to pemetinib, 63% had a response that lasted 6 months or longer, and 18% had a response that lasted 12 months or longer. It can be seen that when used as second-line treatment for cholangiocarcinoma with FGFR2 fusion/rearrangement, the tumors of most patients can be controlled, and the tumors of some patients can be significantly reduced or improved. Therefore, pemetinib has a significant effect on many patients with cholangiocarcinoma and helps patients with cholangiocarcinoma achieve remission that lasts longer. Common side effects of pemetinib are diarrhea, nausea, change in taste, vomiting, loss of appetite, weight loss, constipation, stomach pain, mouth sores, dry mouth and/or dry skin; decreased urine output; or rapid heartbeat.

Pemetinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemetinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.